Listed by the USPTO as DUFFY, PATRICIA ANN
Tech Center 1600 • Art Units: 1644 1645 1647
This examiner grants 53% of resolved cases
Patricia Ann Duffy, in Tech Center 1600 and Art Unit 1644, has 573 resolved cases. The allowance rate is 52.9 percent. The median days to allowance is 1327.
The interview lift is 33.9 percent. Glaxosmithkline Biologicals S.A., Board of Regents of the University of Texas System, and University of Florida Research Foundation Inc. are the top companies. These companies represent the primary corporate interests in the examiner's docket.
WOLF GREENFIELD & SACKS, P.C., BALLARD SPAHR LLP, and Barron & Young PLLC are the top firms. The 33.9 percent lift is significant. Practitioners should use this lift to improve the 52.9 percent allowance rate and navigate the 1327-day median timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18178819 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18097461 | BACILLUS SP. PRODUCING BIOFLOCCULANT AND BIOSURFACTANT AND USE THEREOF | Final Rejection | ZHEJIANG UNIVERSITY |
| 18684437 | PAENIBACILLUS STRAINS PRODUCING LOW AMOUNTS OF EXOPOLYSACCARIDES | Non-Final OA | BASF SE |
| 17350898 | IL-10-CONTAINING VACCINES AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18685422 | DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII | Final Rejection | City University of Hong Kong |
| 18506636 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN CHLAMYDIAL INFECTIONS AND DISEASES USING ATTENUATED ANIMAL CHLAMYDIA | Non-Final OA | Board of Regents, The University of Texas System |
| 18318062 | ENDOLYSOSOMAL TARGETING CONJUGATES FOR IMPROVED DELIVERY OF CARGO MOLECULES TO THE ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS | Non-Final OA | Board of Regents of the University of Texas System |
| 18681192 | LEPTOSPIRAL VIRULENCE MODULATING PROTEINS AND USES THEREOF | Non-Final OA | Yale University |
| 18661538 | COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING MALARIA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18580713 | PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18841203 | ANAPLASMA VACCINES AND METHODS OF USE THEREOF | Non-Final OA | Kansas State University Research Foundation |
| 18550659 | PATHOGEN MOIETIES AND USES THEREOF | Final Rejection | University of Iowa Research Foundation |
| 18718636 | VACCINE | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18686089 | Shigella Vaccine | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18256749 | Hyper-Blebbing Bacteria | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17628667 | QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy52.9% of resolved applications examined by Patricia Ann Duffy were allowed (573 resolved cases), compared with 35.9% across Art Unit 1644 over the last five years.
This examiner's interview lift is +33.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Patricia Ann Duffy took 1,327 days on average from filing to allowance.
Patricia Ann Duffy examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
